NIH-funded research NIH-funded research

Diversity of PDE2A Signaling in Traumatic Brain Injury and Alzheimer’s Disease

Official title: Diversity of Phosphodiesterase 2A Signaling in Traumatic Brain Injury and Alzheimer’s Disease.

Funded at Rutgers Biomedical and Health Sciences · NIH-11238201 · Data updated 2026-11-12

This project explores how an enzyme called PDE2A affects brain cell energy and inflammation after brain injury, to understand its link to Alzheimer’s-related dementia.

More s Disease research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionRutgers Biomedical and Health Sciences
NIH-funded
Lab location1 site (Newark, UNITED STATES)
Project startSeptember 5, 2026
Project endAugust 31, 2029
Funding year2026
Award (this year)$1,840,615
NIH project number1RF1NS145336-01
Project IDNIH-11238201 on NIH RePORTER

Who could benefit from this research

Could help

Patients with traumatic brain injury and individuals at risk for AD/ADRD may benefit from future translational applications of this work.

Less likely to help

This research is focused on disease mechanisms and may not provide direct benefits to individuals without TBI or AD-related conditions.

What this research studies

If you or a loved one has had a traumatic brain injury, this research looks at how a specific brain enzyme (PDE2A) changes with injury and may contribute to later dementia. The scientists will study mitochondria, the cell’s energy factories, and how PDE2A influences important channels and DNA leakage that can trigger inflammation. By examining the signaling pathways in brain cells, they hope to uncover mechanisms that connect TBI to Alzheimer's disease and related dementias. The goal is to identify potential targets that could protect brain energy and reduce neurodegeneration after injury.

Why it matters

Potential benefit: Understanding PDE2A’s role could lead to strategies that protect brain energy and slow progression to dementia after TBI.

How similar studies have gone: Previous work suggests PDE2A inhibitors can influence mitochondrial function and neuroinflammation, supporting a plausible link to dementia outcomes.

Where this research is happening

  • Rutgers Biomedical and Health Sciences
    Newark, United States
    Active

Researchers

  • Principal investigator: Xu, Ying — Rutgers Biomedical and Health Sciences
  • Study coordinator: Xu, Ying

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.